Investigating the Launch of 'Fexuclue' for Erosive Esophagitis in India

The question asks to identify the specific organisation that launched the innovative drug named 'Fexuclue' in India in April 2025. This drug is intended for the treatment of a medical condition known as Erosive Esophagitis.

Understanding Erosive Esophagitis

Erosive Esophagitis is a condition where the lining of the esophagus (the tube connecting the throat and stomach) becomes inflamed and damaged, often resulting in sores or erosions. This can cause symptoms like difficulty swallowing, pain, and heartburn.

Analyzing Pharmaceutical Organisations in India

Several major pharmaceutical companies operate in India, contributing significantly to healthcare advancements. The options provided represent prominent players in the Indian pharmaceutical sector:

• Bharat Biotech: Known for vaccine development.
• Serum Institute of India: A major vaccine manufacturer.
• Sun Pharmaceutical Industries: A large, multinational pharmaceutical company.
• Dr. Reddy's Laboratories: Another leading Indian pharmaceutical company.

Identifying the Organisation Behind 'Fexuclue'

The introduction of a new drug like 'Fexuclue' requires significant research, development, and regulatory approval. Based on industry news and company announcements around April 2025, Sun Pharmaceutical Industries launched this specific drug in India to address Erosive Esophagitis.

Therefore, Sun Pharmaceutical Industries is the organisation responsible for bringing the innovative drug 'Fexuclue' to the Indian market for treating patients suffering from Erosive Esophagitis.